CA2407953A1 - Stented trabecular shunt and methods thereof - Google Patents
Stented trabecular shunt and methods thereof Download PDFInfo
- Publication number
- CA2407953A1 CA2407953A1 CA002407953A CA2407953A CA2407953A1 CA 2407953 A1 CA2407953 A1 CA 2407953A1 CA 002407953 A CA002407953 A CA 002407953A CA 2407953 A CA2407953 A CA 2407953A CA 2407953 A1 CA2407953 A1 CA 2407953A1
- Authority
- CA
- Canada
- Prior art keywords
- shape
- trabecular
- outlet section
- trabecular shunt
- memory nitinol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
- A61F9/007—Methods or devices for eye surgery
- A61F9/00781—Apparatus for modifying intraocular pressure, e.g. for glaucoma treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00831—Material properties
- A61B2017/00867—Material properties shape memory effect
Landscapes
- Health & Medical Sciences (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Prostheses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
A stented trabecular shunt (65) for transporting aqueous humor to bypassing diseased trabecular meshwork from an anterior chamber of an eye to an existing outflow pathway comprising an inlet section (62) and an outlet section (64), wherein the outlet section comprises a stenting element (68) that is expandable and adapted for stabilizing the outlet section within an existing outflow pathway. The stenting element may be made of a shape-memory Nitinol, the shape-memory Nitinol having a preshape and a shape transition temperature, wherein the shape-memory Nitinol expands to its preshape when the shape-memory Nitinol is heated by RF energy or an external heat source to above the shape transition temperature.
Description
STENTED TRABECULAR SHUNT AND METHODS THEREOF
FIELD OF THE INVENTION
The present invention generally relates to glaucoma devices for the reduction of ocular pressure in the anterior chamber of an eye. Mare particularly, the present invention relates to the treatment of glaucoma by trabecular bypass surgery and a stented trabecular shunt which bypasses diseased trabecular meshwork at the level of trabecular meshwork and restores existing outflow pathways.
BACKGROUND OF THE INVENTION
A stent is a generally longitudinal tubular device formed of biocompatible material, preferably a metallic or a plastic material, which is useful in the treatment of stenosis, strictures or aneurysms in body vessels such as blood vessels or Schlemm's canal of an eye. It is well known to employ a stent for the treatment of diseases of various body vessels and for stabilization the stent in a conduit. The device may be implanted within the conduit to reinforce collapsing, partially occluded, weakened or abnormally dilated sections of the conduit. One type of stents is employed after angioplasty of a blood vessel to prevent restenosis of the diseased vessel. Stents may he useful in other body conduits such as the urological tract, bile duct, Schlemm's canal, or aqueous vein in an eye.
Stents generally include an open flexible configuration. The stent configuration allows the stent to be configured in a radially or longitudinally compressed state for insertion to an appropriate site. Once properly positioned in place, the stent is expanded so as to supportlreinforce the conduit or stabilize itself inside the conduit. Radial expansion of the stent may be accomplished by an inflatable balloon attached to a catheter or the stent may be of the self-expanding type that will radially expand once deployed from the end portion of a delivery catheter. One stent example is U.S. Pat. No. 4,733,665 to Palmaz, which is incorporated herein by reference.
In the aforementioned conventional process of expanding a stent, it does not provide mechanisms for axial expansion. To expand a stent or stented device in either radial or axial direction, it would be beneficial to activate the expansion step by an expansion mechanism without any mechanical interference on the device, such as a balloon. To deploy an expandable stented trabecular shunt of less than one millimeter, it is very difficult to apply an inflatable balloon inside that shunt as a deploying mechanism. It is equally difficult to deliver a self-expanding stented shunt of less than one millimeter using a delivery catheter. Gentle heat may be the only means far applying to a temperature sensitive shape-memory Nitinol stent so that the stent is expanded at a temperature above its shape-memory transitional temperature.
In a copending patent application Ser. Nr. 091549,350, filed 411412000, entitled "Apparatus and method for treating glaucoma", a glaucoma device is disclosed for transporting the aqueous humor to bypassing diseased trabecular meshwork at a level of the trabecular meshwork and using existing outflow pathways. The glaucoma device may comprise an elongated tubular element having an outlet section and an inlet section, wherein the outlet section is positioned inside the existing outflow pathway, such as Schlemm's canal. The outlet section of the glaucoma device inside Schlemm's canal may be stented so as to stabilize the device at its implanted location. The co-pending application (091549,350) is incorporated herein by reference.
The human eye is a specialized sensory organ capable of light reception and able to receive visual images.
The main parts of the eye are the cornea, the iris, the lens, the retina, the trabecular meshwork, and outflow pathways, such as Schlemm's canal. The trabecular meshwork serves as a drainage channel located between the cornea and the surrounding white portion of the eye. The trabecular meshwork maintains a balanced pressure in the anterior chamber of the eye by draining excess aqueous humor.
About two percent of people in the United States have glaucoma. Glaucoma is a group of eye diseases encompassing a broad spectrum of clinical presentation, etiology and treatment modality that causes pathological changes in the optic disk and corresponding visual field loss resulting in blindness if untreated. Intraocular pressure elevation is the major treatable etiologic factor in all glaucomas.
In glaucomas associated with an elevation in eye pressure the source of resistance to outflow is mainly in the trabecular meshwork. The tissue of the trabecular meshwork allows the "aqueous" to enter Schlemm s canal, which then empties, into aqueous collector channels in the posterior wall of Schlemm s canal and then into aqueous veins. The aqueous or aqueous humor is a transparent liquid that fills the region between the cornea at the front of the eye and the lens. The aqueous humor is constantly secreted by the ciliary body around the lens, so there is a continuous flow of the aqueous humor from the ciliary body to the eye's front chamber. The eye's pressure is determined by a balance between the production of aqueous and its exit through trabecular meshwork (major route) or uveal scleral outflow (minor routel. The trabecular meshwork is located between the outer rim of the iris and the back of the cornea. The portion of the trabecular meshwork adjacent to Schlemrri s canal causes most of the resistance to aqueous outflow (juxtacanilicular meshwork).
Therefore, there is a great clinical need for the treatment of glaucoma by a method that would be faster, safer and less expensive than currently available modalities. Trabecular bypass surgery is an innovative surgery which uses a trabecular shunt device to bypass diseased trabecular meshwork alone at the level of trabecular meshwork and uselrestore existing outflow pathways. The object of the present invention is to provide a stented trabecular shunt and methods for treating elevated intraocular pressure in a manner which is simple, effective, disease site-specific and can be performed on an outpatient basis. The stenting portion of the trabecufar shunt is to be deployed by gentle heat and adapted to stabilize the shunt inside Schlemm's canal even under constant movement of the eye lens.
Summary of the Invention In general, it is an object of the present invention for the treatment of glaucoma by trabecular bypass surgery and a stented trabecular shunt which bypasses diseased trabecular meshwork at the level of trabecular meshwork and restores existing outflow pathways. It is another object to provide a method for placing the stented trabecular shunt for transporting aqueous humor to bypassing diseased trabecular meshwork. It is a further object of the present invention to provide a stented trabecular shunt comprising an inlet section and an outlet section, wherein the outlet section comprises a stenting element that is retractablelexpandable and adapted for stabilizing the outlet section within an existing outflow pathway for aqueous humor disposition.
In one preferred embodiment, the stenting element may be made of a shape-memory Nitinal. The shape memory Nitinol has a preshape and a shape transition temperature, wherein the crimped shape-memory Nitinol expands to its preshape when the shape-memory Nitinol is heated to above the shape transition temperature. The shape transition temperature for the shape-memory Nitinol is preferably between about 40°C and 90°C. The transition temperature is further preferred between about 40°C and about 50°C. A Nitinol device is well known to have a preshape and a transition temperature for the Nitinol device to reverse to its preshape.
The stenting element may be expanded by heat above the shape transition temperature. In one embodiment, a source of RF energy is adapted for delivering RF energy through an electrical conductor to the stenting element and heating the stenting element to above the shape transition temperature of the shape-memory Nitinol. The RF current is preferably within the range of 50 to 2,000 kHz. In another embodiment, an external heat source is provided and adapted for heating the stenting element to above the shape transition temperature of the shape-memory Nitinol.
The stenting element in this invention may include a permanent implantable stent, or a temporary stent, wherein the temporary stent is defined in this invention as a stent that is expandable inside a conduit and removed thereafter from the conduit of a patient. The configuration of the stenting element may be selected from a group consisting of a coif stent, a Nitinol stmt, a mesh stent, a scaffold stent, a sleeve stent, a permeable stent, a porous stent made of porous material for drug delivery, a U-shape stent, a combination of the above, and the like.
In a preferred embodiment, the exterior surface of the stenting element of the present invention may have fluorine-containing coating. The exterior surface of a stenting element having fluorine-containing compound is to render the tissue-contacting surface biocompatible. It is well known to one who is skilled in the art that a fluorinated surface has low surface energy and is highly biocompatible and hemo-compatible. The "fluorine-containing surface' is synonymous in this invention to "fluorinated surface', which substrate surface is covered or impregnated with fluorine, fluoride, other fluorine-containing compounds, and the like. The fluorine-containing coating and its process may be selected from a group consisting of glow discharge coating, adhesive coating, impregnating coating, compound coating, dip coating, paste coating, and sintering. The dip coating and paste coating on a metallic substrate followed by sintering has been extensively used to coat the frying pans and the like, and is well known to one who is skilled in the art. One class of the fluorine-containing material used in the coating process has a tradename of Teflon~ (a tradename of Du Pont Company).
In an additional alternate embodiment, the stenting element is embedded within a biocompatible material selected from a group consisting of silicone, polyurethane, porous material, expanded polytetrafluoroethylene, semi-permeable membrane, elastomer, and mixture of said biocompatible material thereof. The embedding material usually obstructs very little to the expansion process of the stenting element.
The trabecular shunt of the present invention may further comprise a lumen throughout the inlet section and the outlet section for transporting aqueous humor to bypassing diseased trabecular meshwork from an anterior chamber of an eye to the existing outflow pathway. The outlet section may comprise at least one opening for venting aqueous humor. The at least one opening is connected to and in communication with the lumen of the trabecular shunt. Furthermore, the outlet section may comprise an elongated trough along the outlet section for venting aqueous humor into the existing outflow pathway, wherein the elongated trough is connected to and in communication with the lumen of the trabecular shunt.
In accordance with the present invention, the trabecular shunt may be made of a biocompatible material selected from a group consisting of semi-permeable polymer, polyvinyl alcohol, polyvinyl pyrolidone, collagen, heparinized collagen, polytetrafluoroethylene, expanded polytetrafluoroethylene, fluorinated polymer, fluorinated elastomer, flexible fused silica, polyolefin, polyester, polyimide, polysilison, silicone, polyurethane, Nylon, polypropylene, hydroxyapetite, precious metal, and mixture of said biocompatible material thereof.
A method of placing a trabecular shunt for transporting aqueous humor to bypassing diseased trabecular meshwork may comprise the steps of (a) creating an opening through diseased trabecular meshwork; (b) advancing the outlet section through the opening into the existing outflow pathway; and (c) expanding the stenting element for stabilizing the outlet section within the existing outflow pathway.
In an alternate embodiment, a method of delivering a trabecular shunt to bypassing diseased trabecular meshwork, the trabecular shunt comprises an inlet section and an outlet section, wherein the outlet section comprises a stenting element that is retracted during a delivery phase. The method may comprise the steps of (a) creating an opening through diseased trabecular meshwork at a size for the outlet section with a retracted stenting element to pass through; (b) advancing the outlet section through the opening into an existing outflow pathway; and (c) expanding the retracted stenting element for stabilizing the outlet section within the existing outflow pathway The method and the retractablelexpandable trabecular shunt of the present invention have several significant advantages over other known systems to treat the glaucoma. In particular, the stented trabecular shunt and methods for treating elevated intraocular pressure in a manner that the stenting portion of the trabecular shunt is to stabilize the shunt inside Schlemm's canal even under constant movement of the eyeball.
Brief Description of the Drawings Additional objects and features of the present invention will become more apparent and the invention itself will be best understood from the following Detailed Description of Exemplary Embodiments, when read with reference to the accompanying drawings.
FIG. 1 is a sectional view of a stenting element having expandablelretractable capabilities at a retracted state constructed in accordance to the principles of the present invention.
FIG. 2 is an exterior sectional view of a stenting element having expandablelretractable capabilities at a radially expanded state, constructed in accordance to the principles of the present invention.
FIG. 3 is a sectional view of an eye for illustration purposes.
FIG. 4 is a close-up sectional view, showing the anatomical diagram and relative locations of the trabecular meshwork, Schlemm's canal and the anterior chamber of an eye.
_q._ FIG. 5 is an embodiment of the stented trabecular shunt device constructed according to the principles of the invention.
FIG. 6 is a schematic diagram of RF energy delivery mechanism as one method for activating the expansionlretraction of the stented trabecular shunt.
FIG. 7 is a perspective view of a stented trabecular shunt that has its outlet section radially expanded for stabilization itself inside Schlemm's canal.
DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS
Referring to FIGS. 1 to 7, what is shown is an embodiment of a stented trabecular shunt for transporting aqueous humor to bypassing diseased trabecular meshwork at the level of trabecular meshwork and restores existing outflow pathways and methods thereof.
FIG. 1 shows a section of the stenting element 43 having a crimping or collapsing capability at a non-deployed state, constructed in accordance to the principles of the present invention. As shown in FIG. 1, the stenting element 43 has its radially outer boundaries 44A, 44B at a non-deployed state.
These outer boundaries 44A, 44B at a non-deployed state is smaller than the radially boundaries 44C, 44D at a deployed state of FIG. 2. When the stenting element 43 is to be collapsed, the outer boundaries at a collapsedlretracted state is smaller than the expanded boundaries 44C, 44D so that the stenting element can be delivered at its smallest size through diseased trabecular meshwork into the existing outflow pathway of an eye. The interior luminal portion 45A. 45B is to contact a body fluid, such as aqueous humor in an existing outflow pathway, while the exterior portion 46A, 46B is to contact tissue when the stenting element 43 is deployed to support and stabilize the outlet section of the stented trabecular shunt inside an existing outflow pathway, such as Schlemm's canal.
FIG. 2 shows an exterior sectional view of a stenting element having expandablelretractable capabilities at a radially expanded state, constructed in accordance to the principles of the present invention. As shown in FIG. 2, the stenting element 43 has its radially outer boundaries 44C, 44D at an expanded or deployed state. The exterior surface 46A, 46B is to contact tissue when the stenting element 43 is deployed to support and stabilize the outer section of the trabecular shunt inside an existing outflow pathway.
For background illustration purposes, FIG. 3 shows a sectional view of an eye 10, while FIG. 4 shows a close-up view, showing the relative anatomical locations of trabecular meshwork, the anterior chamber, and Schlemm's canal. Thick collagenous tissue known as sclera 11 covers the entire eye 10 except that portion covered by the cornea 12. The cornea 12 is a thin transparent tissue that focuses and transmits light into the eye and the pupil 14 which is the circular hole in the center of the iris 13 (colored portion of the eye). The cornea 12 merges into the sclera 11 at a juncture referred to as the limbus 15. The ciliary body 16 begins internally in the eye and extends along the interior of the sclera 11 and becomes the choroid 17. The choroid 17 is a vascular layer of the eye underlying retina 18. The optic nerve 19 transmits visual information to the brain and is sequentially destroyed by glaucoma.
The anterior chamber 20 of the eye 10, which is bound anteriorly by the cornea 12 and posteriorly by the iris 13 and lens 26, is filled with aqueous. Aqueous is produced primarily by the ciliary body 16 and reaches the anterior chamber angle 25 formed between the iris 13 and the cornea 12 through the pupil 14. In a normal eye, the aqueous is removed through the trabecular meshwork 21. Aqueous passes through trabecular meshwork 21 into Schlemm's canal 22 and thereafter through the aqueous veins 23 which merge with blood-carrying veins and into venous circulation. Intraocular pressure of the eye is maintained by the intricate balance of secretion and outflow of the aqueous in the manner described above. Glaucoma is characterized by the excessive buildup of aqueous fluid in the anterior chamber 20 which produces an increase in intraocular pressure (fluids are relatively incompressible and pressure is directed equally to all areas of the eye).
As shown in FIG. 4, the trabecular meshwork 21 constitutes a small portion of the sclera 11. It is understandable that creating a hole or opening for implanting a device through the tissues of the conjunctiva 24 and sclera 11 is relatively a major surgery as compared to a surgery for implanting a shunt through the trabecular meshwork 21 only. A device 65 of the present invention for either using andlor restoring existing outflow pathways positioned through the trabecular meshwork 21 is illustrated in FIG. 7.
FIG. 5 is an embodiment of the stented trabecular shunt device constructed according to the principles of the invention. A stented trabecular shunt 65 for transporting aqueous humor to bypassing diseased trabecular meshwork comprises an inlet section 62 and an outlet section 64, wherein the outlet section 64 comprises a stenting element 68 that is expandablelcrimpable and adapted for stabilizing the outlet section 64 within an existing outflow pathway for aqueous humor disposition. In an alternate embodiment, an optional middle section 63 is located between the inlet section 62 and the outlet section 64.
An optional ridge or flange 84 at about the junction of the inlet section 62 into the trabecular meshwork is provided for device placement purposes. The appropriate length of the inlet section may be between about 300 microns to 2 millimeters. The inlet section may be at an angle to the outlet section 64 so that the inlet end of the inlet section is safely positioned inside the anterior chamber. The inlet section 62 has an outer diameter generally around 100 microns to 1 millimeter while the lumen 61 is preferably between 50 microns to about 300 microns. The outlet section 64 is about perpendicular to or at an angle with the inlet section 62 so that the outlet section is placed inside an existing outflow pathway, such as Schlemm's canal without excess stress.
The outlet section has a length of between about 200 microns to about 2 millimeters. The diameter of the outlet section may be about 100 microns to about 1 millimeter, The stenting element 68 may be made of a shape-memory Nitinol. The shape-memory Nitinol has a preshape to form an expanded structure 67 and a shape transition temperature. During the delivery stage or non-deployed state, the shape-memory Nitinol is crimped at a retracted structure 66 for easy insertion through the trabecular meshwork.
The shape-memory Nitinol expands to its preshape 67 when the shape-memory Nitinol is heated to above the shape transition temperature. As shown in FIG. 5, a retracted side 69 of the stenting element at a non-deployed state is expanded to the expanded side 70 of the stenting element at the deployed state. The "deployed state" in this invention refers to the preshape of the shape-memory Nitinol after a temperature above its shape transition temperature is reached. Heat can also be provided from an external heat sources, such as a heating pad, a warm cloth, a bag of warm water, remotely deliverable heat, electromagnetic force, and the like.
In a further embodiment, the stented trabecular shunt comprises a lumen 61 throughout the inlet section 62, the optional middle section 63, and the outlet section 64 for transporting aqueous humor to bypassing diseased trabecular meshwork 21 from an anterior chamber 20 of an eye to the existing outflow pathway 22. The outlet section may comprise at least one opening for venting aqueous humor, the at least one opening being connected to and in communication with the lumen of the trabecular shunt. In a still further embodiment, the outlet section 64 may comprise an elongated opening, trough, or groove 71 along an axis of the outlet section 64 for venting aqueous humor into the existing outflow pathway. The elongated trough 71 is connected to and in communication with the lumen 61 of the trabecular shunt 65.
FIG. 6 shows a schematic diagram of a RF generating means for causing the stenting element of the outlet section to expand radially, circumferentially, axially, or combination thereof. The direction of expansion is related to the design of the stenting element and type of shape-memory Nitinol used. A RF
generator 51 is connected to an expandablelretractable outlet section 64 of a stented trabecular shunt 65 through an electrical guidewire conductor 52. In one embodiment, the stenting element 68 is to contact the underlying tissue of the Schlemm's canal 22 at a non-deployed state. A DIP (dispersive indifferent pad) type pad 56, that contacts a patient, is connected to the Indifferent Electrode Connector on the RF generator 51. Therefore, the RF
energy delivery becomes effective when a close circuit from a RF generator 51 through a stenting element, a patient and returning to the RF generator is farmed.
A temperature sensor 57 may also used to measure the tissue temperature and is relayed through a temperature sensing wire 58 and a closed-loop temperature controller 59 for controlling the RF energy delivered. Heat to the tissue is controlled by the power of the RF energy delivered and by the delivery duration. The heat 53 to stented outlet section causes the outlet section to expand 55 when a stenting element needs to be expanded for stabilizing itself inside a confined conduit.
The stenting element portion of the scented trabecular shunt may comprise the fluorine-containing coating to render the surface more biocompatible, wherein the coating may be selected from a group consisting of glow discharge coating, adhesive coating, impregnating coating, compound coating, dip coating, paste coating, and sintering. The fluorination process via glow discharge method is well known to one who is skilled in the art.
FIG. 7 shows a perspective view of a stented trabecular shunt 65 that has its outlet section 64 radially expanded for stabilization itself inside Schlemm's canal 22. In an alternate embodiment, the expandable outlet section can be expanded longitudinally along an axis of the outlet section 64 or a combination of radial and longitudinal expansion. A method of placing a trabecular shunt 65 for transporting aqueous humor to bypassing diseased trabecular meshwork 21 may comprise the steps of: (a) creating an opening through diseased trabecular meshwork 21 so that the outlet section 64 can pass through; (b) advancing the outlet section 64 through the opening into the existing outflow pathway; and (c) expanding the stenting element from a retractedlcrimped position 66 to an expandedldeployed position 67 for stabilizing the outlet section 64 within the existing outflow pathway. In a preferred embodiment, the existing outflow pathway is Schlemm's canal 22, wherein aqueous duct 23 located at the internal portion 82 of the sclera transports the aqueous humor out of the Schlemm's canal 22. The purpose of trough 71 at the rear side of the outlet section 64 is provided and adapted not to interfere the outflow aqueous duct 23.
Alternately, the trabecular shunt comprises an inlet section and an outlet section, wherein the outlet section comprises a stenting element that is retractedlcrimped during a delivery phase. A method of delivering a trabecular shunt to bypassing diseased trabecular meshwork may comprise the steps of: (a) creating an opening through diseased trabecular meshwork at a size just enough for the outlet section with a retracted stenting element to pass through; (b) advancing the outlet section through the opening into an existing outflow pathway; and (c) expanding the retractedlcrimped stenting element for stabilizing the outlet section within the existing outflow pathway From the foregoing description, it should now be appreciated that a stented trabecular shunt and methods thereof have been disclosed. While the invention has been described with reference to a specific embodiment, the description is illustrative of the invention and is not to be construed as limiting the invention. Various modifications and applications may occur to those who are skilled in the art, without departing from the true spirit and scope of the invention, as described by the appended claims.
_g_
FIELD OF THE INVENTION
The present invention generally relates to glaucoma devices for the reduction of ocular pressure in the anterior chamber of an eye. Mare particularly, the present invention relates to the treatment of glaucoma by trabecular bypass surgery and a stented trabecular shunt which bypasses diseased trabecular meshwork at the level of trabecular meshwork and restores existing outflow pathways.
BACKGROUND OF THE INVENTION
A stent is a generally longitudinal tubular device formed of biocompatible material, preferably a metallic or a plastic material, which is useful in the treatment of stenosis, strictures or aneurysms in body vessels such as blood vessels or Schlemm's canal of an eye. It is well known to employ a stent for the treatment of diseases of various body vessels and for stabilization the stent in a conduit. The device may be implanted within the conduit to reinforce collapsing, partially occluded, weakened or abnormally dilated sections of the conduit. One type of stents is employed after angioplasty of a blood vessel to prevent restenosis of the diseased vessel. Stents may he useful in other body conduits such as the urological tract, bile duct, Schlemm's canal, or aqueous vein in an eye.
Stents generally include an open flexible configuration. The stent configuration allows the stent to be configured in a radially or longitudinally compressed state for insertion to an appropriate site. Once properly positioned in place, the stent is expanded so as to supportlreinforce the conduit or stabilize itself inside the conduit. Radial expansion of the stent may be accomplished by an inflatable balloon attached to a catheter or the stent may be of the self-expanding type that will radially expand once deployed from the end portion of a delivery catheter. One stent example is U.S. Pat. No. 4,733,665 to Palmaz, which is incorporated herein by reference.
In the aforementioned conventional process of expanding a stent, it does not provide mechanisms for axial expansion. To expand a stent or stented device in either radial or axial direction, it would be beneficial to activate the expansion step by an expansion mechanism without any mechanical interference on the device, such as a balloon. To deploy an expandable stented trabecular shunt of less than one millimeter, it is very difficult to apply an inflatable balloon inside that shunt as a deploying mechanism. It is equally difficult to deliver a self-expanding stented shunt of less than one millimeter using a delivery catheter. Gentle heat may be the only means far applying to a temperature sensitive shape-memory Nitinol stent so that the stent is expanded at a temperature above its shape-memory transitional temperature.
In a copending patent application Ser. Nr. 091549,350, filed 411412000, entitled "Apparatus and method for treating glaucoma", a glaucoma device is disclosed for transporting the aqueous humor to bypassing diseased trabecular meshwork at a level of the trabecular meshwork and using existing outflow pathways. The glaucoma device may comprise an elongated tubular element having an outlet section and an inlet section, wherein the outlet section is positioned inside the existing outflow pathway, such as Schlemm's canal. The outlet section of the glaucoma device inside Schlemm's canal may be stented so as to stabilize the device at its implanted location. The co-pending application (091549,350) is incorporated herein by reference.
The human eye is a specialized sensory organ capable of light reception and able to receive visual images.
The main parts of the eye are the cornea, the iris, the lens, the retina, the trabecular meshwork, and outflow pathways, such as Schlemm's canal. The trabecular meshwork serves as a drainage channel located between the cornea and the surrounding white portion of the eye. The trabecular meshwork maintains a balanced pressure in the anterior chamber of the eye by draining excess aqueous humor.
About two percent of people in the United States have glaucoma. Glaucoma is a group of eye diseases encompassing a broad spectrum of clinical presentation, etiology and treatment modality that causes pathological changes in the optic disk and corresponding visual field loss resulting in blindness if untreated. Intraocular pressure elevation is the major treatable etiologic factor in all glaucomas.
In glaucomas associated with an elevation in eye pressure the source of resistance to outflow is mainly in the trabecular meshwork. The tissue of the trabecular meshwork allows the "aqueous" to enter Schlemm s canal, which then empties, into aqueous collector channels in the posterior wall of Schlemm s canal and then into aqueous veins. The aqueous or aqueous humor is a transparent liquid that fills the region between the cornea at the front of the eye and the lens. The aqueous humor is constantly secreted by the ciliary body around the lens, so there is a continuous flow of the aqueous humor from the ciliary body to the eye's front chamber. The eye's pressure is determined by a balance between the production of aqueous and its exit through trabecular meshwork (major route) or uveal scleral outflow (minor routel. The trabecular meshwork is located between the outer rim of the iris and the back of the cornea. The portion of the trabecular meshwork adjacent to Schlemrri s canal causes most of the resistance to aqueous outflow (juxtacanilicular meshwork).
Therefore, there is a great clinical need for the treatment of glaucoma by a method that would be faster, safer and less expensive than currently available modalities. Trabecular bypass surgery is an innovative surgery which uses a trabecular shunt device to bypass diseased trabecular meshwork alone at the level of trabecular meshwork and uselrestore existing outflow pathways. The object of the present invention is to provide a stented trabecular shunt and methods for treating elevated intraocular pressure in a manner which is simple, effective, disease site-specific and can be performed on an outpatient basis. The stenting portion of the trabecufar shunt is to be deployed by gentle heat and adapted to stabilize the shunt inside Schlemm's canal even under constant movement of the eye lens.
Summary of the Invention In general, it is an object of the present invention for the treatment of glaucoma by trabecular bypass surgery and a stented trabecular shunt which bypasses diseased trabecular meshwork at the level of trabecular meshwork and restores existing outflow pathways. It is another object to provide a method for placing the stented trabecular shunt for transporting aqueous humor to bypassing diseased trabecular meshwork. It is a further object of the present invention to provide a stented trabecular shunt comprising an inlet section and an outlet section, wherein the outlet section comprises a stenting element that is retractablelexpandable and adapted for stabilizing the outlet section within an existing outflow pathway for aqueous humor disposition.
In one preferred embodiment, the stenting element may be made of a shape-memory Nitinal. The shape memory Nitinol has a preshape and a shape transition temperature, wherein the crimped shape-memory Nitinol expands to its preshape when the shape-memory Nitinol is heated to above the shape transition temperature. The shape transition temperature for the shape-memory Nitinol is preferably between about 40°C and 90°C. The transition temperature is further preferred between about 40°C and about 50°C. A Nitinol device is well known to have a preshape and a transition temperature for the Nitinol device to reverse to its preshape.
The stenting element may be expanded by heat above the shape transition temperature. In one embodiment, a source of RF energy is adapted for delivering RF energy through an electrical conductor to the stenting element and heating the stenting element to above the shape transition temperature of the shape-memory Nitinol. The RF current is preferably within the range of 50 to 2,000 kHz. In another embodiment, an external heat source is provided and adapted for heating the stenting element to above the shape transition temperature of the shape-memory Nitinol.
The stenting element in this invention may include a permanent implantable stent, or a temporary stent, wherein the temporary stent is defined in this invention as a stent that is expandable inside a conduit and removed thereafter from the conduit of a patient. The configuration of the stenting element may be selected from a group consisting of a coif stent, a Nitinol stmt, a mesh stent, a scaffold stent, a sleeve stent, a permeable stent, a porous stent made of porous material for drug delivery, a U-shape stent, a combination of the above, and the like.
In a preferred embodiment, the exterior surface of the stenting element of the present invention may have fluorine-containing coating. The exterior surface of a stenting element having fluorine-containing compound is to render the tissue-contacting surface biocompatible. It is well known to one who is skilled in the art that a fluorinated surface has low surface energy and is highly biocompatible and hemo-compatible. The "fluorine-containing surface' is synonymous in this invention to "fluorinated surface', which substrate surface is covered or impregnated with fluorine, fluoride, other fluorine-containing compounds, and the like. The fluorine-containing coating and its process may be selected from a group consisting of glow discharge coating, adhesive coating, impregnating coating, compound coating, dip coating, paste coating, and sintering. The dip coating and paste coating on a metallic substrate followed by sintering has been extensively used to coat the frying pans and the like, and is well known to one who is skilled in the art. One class of the fluorine-containing material used in the coating process has a tradename of Teflon~ (a tradename of Du Pont Company).
In an additional alternate embodiment, the stenting element is embedded within a biocompatible material selected from a group consisting of silicone, polyurethane, porous material, expanded polytetrafluoroethylene, semi-permeable membrane, elastomer, and mixture of said biocompatible material thereof. The embedding material usually obstructs very little to the expansion process of the stenting element.
The trabecular shunt of the present invention may further comprise a lumen throughout the inlet section and the outlet section for transporting aqueous humor to bypassing diseased trabecular meshwork from an anterior chamber of an eye to the existing outflow pathway. The outlet section may comprise at least one opening for venting aqueous humor. The at least one opening is connected to and in communication with the lumen of the trabecular shunt. Furthermore, the outlet section may comprise an elongated trough along the outlet section for venting aqueous humor into the existing outflow pathway, wherein the elongated trough is connected to and in communication with the lumen of the trabecular shunt.
In accordance with the present invention, the trabecular shunt may be made of a biocompatible material selected from a group consisting of semi-permeable polymer, polyvinyl alcohol, polyvinyl pyrolidone, collagen, heparinized collagen, polytetrafluoroethylene, expanded polytetrafluoroethylene, fluorinated polymer, fluorinated elastomer, flexible fused silica, polyolefin, polyester, polyimide, polysilison, silicone, polyurethane, Nylon, polypropylene, hydroxyapetite, precious metal, and mixture of said biocompatible material thereof.
A method of placing a trabecular shunt for transporting aqueous humor to bypassing diseased trabecular meshwork may comprise the steps of (a) creating an opening through diseased trabecular meshwork; (b) advancing the outlet section through the opening into the existing outflow pathway; and (c) expanding the stenting element for stabilizing the outlet section within the existing outflow pathway.
In an alternate embodiment, a method of delivering a trabecular shunt to bypassing diseased trabecular meshwork, the trabecular shunt comprises an inlet section and an outlet section, wherein the outlet section comprises a stenting element that is retracted during a delivery phase. The method may comprise the steps of (a) creating an opening through diseased trabecular meshwork at a size for the outlet section with a retracted stenting element to pass through; (b) advancing the outlet section through the opening into an existing outflow pathway; and (c) expanding the retracted stenting element for stabilizing the outlet section within the existing outflow pathway The method and the retractablelexpandable trabecular shunt of the present invention have several significant advantages over other known systems to treat the glaucoma. In particular, the stented trabecular shunt and methods for treating elevated intraocular pressure in a manner that the stenting portion of the trabecular shunt is to stabilize the shunt inside Schlemm's canal even under constant movement of the eyeball.
Brief Description of the Drawings Additional objects and features of the present invention will become more apparent and the invention itself will be best understood from the following Detailed Description of Exemplary Embodiments, when read with reference to the accompanying drawings.
FIG. 1 is a sectional view of a stenting element having expandablelretractable capabilities at a retracted state constructed in accordance to the principles of the present invention.
FIG. 2 is an exterior sectional view of a stenting element having expandablelretractable capabilities at a radially expanded state, constructed in accordance to the principles of the present invention.
FIG. 3 is a sectional view of an eye for illustration purposes.
FIG. 4 is a close-up sectional view, showing the anatomical diagram and relative locations of the trabecular meshwork, Schlemm's canal and the anterior chamber of an eye.
_q._ FIG. 5 is an embodiment of the stented trabecular shunt device constructed according to the principles of the invention.
FIG. 6 is a schematic diagram of RF energy delivery mechanism as one method for activating the expansionlretraction of the stented trabecular shunt.
FIG. 7 is a perspective view of a stented trabecular shunt that has its outlet section radially expanded for stabilization itself inside Schlemm's canal.
DETAILED DESCRIPTION OF EXEMPLARY EMBODIMENTS
Referring to FIGS. 1 to 7, what is shown is an embodiment of a stented trabecular shunt for transporting aqueous humor to bypassing diseased trabecular meshwork at the level of trabecular meshwork and restores existing outflow pathways and methods thereof.
FIG. 1 shows a section of the stenting element 43 having a crimping or collapsing capability at a non-deployed state, constructed in accordance to the principles of the present invention. As shown in FIG. 1, the stenting element 43 has its radially outer boundaries 44A, 44B at a non-deployed state.
These outer boundaries 44A, 44B at a non-deployed state is smaller than the radially boundaries 44C, 44D at a deployed state of FIG. 2. When the stenting element 43 is to be collapsed, the outer boundaries at a collapsedlretracted state is smaller than the expanded boundaries 44C, 44D so that the stenting element can be delivered at its smallest size through diseased trabecular meshwork into the existing outflow pathway of an eye. The interior luminal portion 45A. 45B is to contact a body fluid, such as aqueous humor in an existing outflow pathway, while the exterior portion 46A, 46B is to contact tissue when the stenting element 43 is deployed to support and stabilize the outlet section of the stented trabecular shunt inside an existing outflow pathway, such as Schlemm's canal.
FIG. 2 shows an exterior sectional view of a stenting element having expandablelretractable capabilities at a radially expanded state, constructed in accordance to the principles of the present invention. As shown in FIG. 2, the stenting element 43 has its radially outer boundaries 44C, 44D at an expanded or deployed state. The exterior surface 46A, 46B is to contact tissue when the stenting element 43 is deployed to support and stabilize the outer section of the trabecular shunt inside an existing outflow pathway.
For background illustration purposes, FIG. 3 shows a sectional view of an eye 10, while FIG. 4 shows a close-up view, showing the relative anatomical locations of trabecular meshwork, the anterior chamber, and Schlemm's canal. Thick collagenous tissue known as sclera 11 covers the entire eye 10 except that portion covered by the cornea 12. The cornea 12 is a thin transparent tissue that focuses and transmits light into the eye and the pupil 14 which is the circular hole in the center of the iris 13 (colored portion of the eye). The cornea 12 merges into the sclera 11 at a juncture referred to as the limbus 15. The ciliary body 16 begins internally in the eye and extends along the interior of the sclera 11 and becomes the choroid 17. The choroid 17 is a vascular layer of the eye underlying retina 18. The optic nerve 19 transmits visual information to the brain and is sequentially destroyed by glaucoma.
The anterior chamber 20 of the eye 10, which is bound anteriorly by the cornea 12 and posteriorly by the iris 13 and lens 26, is filled with aqueous. Aqueous is produced primarily by the ciliary body 16 and reaches the anterior chamber angle 25 formed between the iris 13 and the cornea 12 through the pupil 14. In a normal eye, the aqueous is removed through the trabecular meshwork 21. Aqueous passes through trabecular meshwork 21 into Schlemm's canal 22 and thereafter through the aqueous veins 23 which merge with blood-carrying veins and into venous circulation. Intraocular pressure of the eye is maintained by the intricate balance of secretion and outflow of the aqueous in the manner described above. Glaucoma is characterized by the excessive buildup of aqueous fluid in the anterior chamber 20 which produces an increase in intraocular pressure (fluids are relatively incompressible and pressure is directed equally to all areas of the eye).
As shown in FIG. 4, the trabecular meshwork 21 constitutes a small portion of the sclera 11. It is understandable that creating a hole or opening for implanting a device through the tissues of the conjunctiva 24 and sclera 11 is relatively a major surgery as compared to a surgery for implanting a shunt through the trabecular meshwork 21 only. A device 65 of the present invention for either using andlor restoring existing outflow pathways positioned through the trabecular meshwork 21 is illustrated in FIG. 7.
FIG. 5 is an embodiment of the stented trabecular shunt device constructed according to the principles of the invention. A stented trabecular shunt 65 for transporting aqueous humor to bypassing diseased trabecular meshwork comprises an inlet section 62 and an outlet section 64, wherein the outlet section 64 comprises a stenting element 68 that is expandablelcrimpable and adapted for stabilizing the outlet section 64 within an existing outflow pathway for aqueous humor disposition. In an alternate embodiment, an optional middle section 63 is located between the inlet section 62 and the outlet section 64.
An optional ridge or flange 84 at about the junction of the inlet section 62 into the trabecular meshwork is provided for device placement purposes. The appropriate length of the inlet section may be between about 300 microns to 2 millimeters. The inlet section may be at an angle to the outlet section 64 so that the inlet end of the inlet section is safely positioned inside the anterior chamber. The inlet section 62 has an outer diameter generally around 100 microns to 1 millimeter while the lumen 61 is preferably between 50 microns to about 300 microns. The outlet section 64 is about perpendicular to or at an angle with the inlet section 62 so that the outlet section is placed inside an existing outflow pathway, such as Schlemm's canal without excess stress.
The outlet section has a length of between about 200 microns to about 2 millimeters. The diameter of the outlet section may be about 100 microns to about 1 millimeter, The stenting element 68 may be made of a shape-memory Nitinol. The shape-memory Nitinol has a preshape to form an expanded structure 67 and a shape transition temperature. During the delivery stage or non-deployed state, the shape-memory Nitinol is crimped at a retracted structure 66 for easy insertion through the trabecular meshwork.
The shape-memory Nitinol expands to its preshape 67 when the shape-memory Nitinol is heated to above the shape transition temperature. As shown in FIG. 5, a retracted side 69 of the stenting element at a non-deployed state is expanded to the expanded side 70 of the stenting element at the deployed state. The "deployed state" in this invention refers to the preshape of the shape-memory Nitinol after a temperature above its shape transition temperature is reached. Heat can also be provided from an external heat sources, such as a heating pad, a warm cloth, a bag of warm water, remotely deliverable heat, electromagnetic force, and the like.
In a further embodiment, the stented trabecular shunt comprises a lumen 61 throughout the inlet section 62, the optional middle section 63, and the outlet section 64 for transporting aqueous humor to bypassing diseased trabecular meshwork 21 from an anterior chamber 20 of an eye to the existing outflow pathway 22. The outlet section may comprise at least one opening for venting aqueous humor, the at least one opening being connected to and in communication with the lumen of the trabecular shunt. In a still further embodiment, the outlet section 64 may comprise an elongated opening, trough, or groove 71 along an axis of the outlet section 64 for venting aqueous humor into the existing outflow pathway. The elongated trough 71 is connected to and in communication with the lumen 61 of the trabecular shunt 65.
FIG. 6 shows a schematic diagram of a RF generating means for causing the stenting element of the outlet section to expand radially, circumferentially, axially, or combination thereof. The direction of expansion is related to the design of the stenting element and type of shape-memory Nitinol used. A RF
generator 51 is connected to an expandablelretractable outlet section 64 of a stented trabecular shunt 65 through an electrical guidewire conductor 52. In one embodiment, the stenting element 68 is to contact the underlying tissue of the Schlemm's canal 22 at a non-deployed state. A DIP (dispersive indifferent pad) type pad 56, that contacts a patient, is connected to the Indifferent Electrode Connector on the RF generator 51. Therefore, the RF
energy delivery becomes effective when a close circuit from a RF generator 51 through a stenting element, a patient and returning to the RF generator is farmed.
A temperature sensor 57 may also used to measure the tissue temperature and is relayed through a temperature sensing wire 58 and a closed-loop temperature controller 59 for controlling the RF energy delivered. Heat to the tissue is controlled by the power of the RF energy delivered and by the delivery duration. The heat 53 to stented outlet section causes the outlet section to expand 55 when a stenting element needs to be expanded for stabilizing itself inside a confined conduit.
The stenting element portion of the scented trabecular shunt may comprise the fluorine-containing coating to render the surface more biocompatible, wherein the coating may be selected from a group consisting of glow discharge coating, adhesive coating, impregnating coating, compound coating, dip coating, paste coating, and sintering. The fluorination process via glow discharge method is well known to one who is skilled in the art.
FIG. 7 shows a perspective view of a stented trabecular shunt 65 that has its outlet section 64 radially expanded for stabilization itself inside Schlemm's canal 22. In an alternate embodiment, the expandable outlet section can be expanded longitudinally along an axis of the outlet section 64 or a combination of radial and longitudinal expansion. A method of placing a trabecular shunt 65 for transporting aqueous humor to bypassing diseased trabecular meshwork 21 may comprise the steps of: (a) creating an opening through diseased trabecular meshwork 21 so that the outlet section 64 can pass through; (b) advancing the outlet section 64 through the opening into the existing outflow pathway; and (c) expanding the stenting element from a retractedlcrimped position 66 to an expandedldeployed position 67 for stabilizing the outlet section 64 within the existing outflow pathway. In a preferred embodiment, the existing outflow pathway is Schlemm's canal 22, wherein aqueous duct 23 located at the internal portion 82 of the sclera transports the aqueous humor out of the Schlemm's canal 22. The purpose of trough 71 at the rear side of the outlet section 64 is provided and adapted not to interfere the outflow aqueous duct 23.
Alternately, the trabecular shunt comprises an inlet section and an outlet section, wherein the outlet section comprises a stenting element that is retractedlcrimped during a delivery phase. A method of delivering a trabecular shunt to bypassing diseased trabecular meshwork may comprise the steps of: (a) creating an opening through diseased trabecular meshwork at a size just enough for the outlet section with a retracted stenting element to pass through; (b) advancing the outlet section through the opening into an existing outflow pathway; and (c) expanding the retractedlcrimped stenting element for stabilizing the outlet section within the existing outflow pathway From the foregoing description, it should now be appreciated that a stented trabecular shunt and methods thereof have been disclosed. While the invention has been described with reference to a specific embodiment, the description is illustrative of the invention and is not to be construed as limiting the invention. Various modifications and applications may occur to those who are skilled in the art, without departing from the true spirit and scope of the invention, as described by the appended claims.
_g_
Claims (20)
1. A trabecular shunt for transporting aqueous humor to bypassing diseased trabecular meshwork comprising an inlet section and an outlet section, wherein said outlet section comprises a stenting element that is expandable and adapted for stabilizing said' outlet section within an existing outflow pathway for aqueous humor disposition.
2. A trabecular shunt according to claim 1, wherein said stenting element is made of a shape-memory Nitinol, the shape-memory Nitinol having a preshape and a shape transition temperature, wherein the shape-memory Nitinol expands to its preshape when said shape-memory Nitinol is heated to above the shape transition temperature.
3. A trabecular shunt according to claim 1, wherein the shape transition temperature for said shape-memory Nitinol is preferably between 40°C and 90°C.
4. A trabecular shunt according to claim 1, wherein surface of the stenting element is covered with fluorine-containing compound.
5. A trabecular shunt according to claim 1, wherein said stenting element is embedded within a biocompatible material selected from a group consisting of silicone, polyurethane, porous material, expanded polytetrafluoroethylene, semi-permeable membrane, elastomer, and mixture of said biocompatible material thereof.
6. A trabecular shunt according to claim 1, wherein said existing outflow pathway is Schlemm's canal.
7. A trabecular shunt according to claim 2 further comprising a source of RF
energy adapted for delivering RF energy through an electrical conductor to said stenting element and heating the stenting element to above the shape transition temperature of said shape-memory Nitinol.
energy adapted for delivering RF energy through an electrical conductor to said stenting element and heating the stenting element to above the shape transition temperature of said shape-memory Nitinol.
8. A trabecular shunt according to claim 2, wherein an external heat-source is provided and adapted for heating the stenting element to above the shape transition temperature of said shape-memory Nitinol.
9. A trabecular shunt according to claim 1, wherein said trabecular shunt comprises a lumen throughout the inlet section and the outlet section for transporting aqueous humor to bypassing diseased trabecular meshwork from an anterior chamber of an eye to the existing outflow pathway.
10. A trabecular shunt according to claim 9, wherein said outlet section comprises at least one opening for venting aqueous humor, said at least one opening being connected to and in communication with said lumen of the trabecular shunt.
11. A trabecular shunt according to claim 9, wherein said outlet section comprises an elongated trough along the outlet section for venting aqueous humor into said existing outflow pathway, said elongated trough being connected to and in communication with said lumen of the trabecular shunt.
12. A trabecular shunt according to claim 1, wherein the trabecular shunt is made of a biocompatible material selected from a group consisting of semi-permeable polymer, polyvinyl alcohol, polyvinyl pyrolidone, collagen, heparinized collagen, polytetrafluoroethylene, expanded polytetrafluoroethylene, fluorinated polymer, fluorinated elastomer, flexible fused silica, polyolefin, polyester, polyimide, polysilison, silicone, polyurethane, Nylon, polypropylene, hydroxyapatite, precious metal, and mixture of said biocompatible material thereof.
13. A method of placing a trabecular shunt for transporting aqueous humor to bypassing diseased trabecular meshwork, the trabecular shunt comprising an inlet section and an outlet section, wherein said outlet section comprises a stenting element that is expandable and adapted for stabilizing said outlet section within an existing outflow pathway; the method comprising steps of:
(a) creating an opening through diseased trabecular meshwork;
(b) advancing the outlet section through said opening into said existing outflow pathway; and (c) expanding said stenting element for stabilizing said outlet section within the existing outflow pathway.
(a) creating an opening through diseased trabecular meshwork;
(b) advancing the outlet section through said opening into said existing outflow pathway; and (c) expanding said stenting element for stabilizing said outlet section within the existing outflow pathway.
14. A method of placing a trabecular shunt for transporting aqueous humor to bypassing diseased trabecular meshwork of claim 13, wherein said stenting element is made of a shape-memory Nitinol that has a preshape and a shape transition temperature; the method of expanding said stenting element comprising heating said shape-memory Nitinol to above the shape transition temperature.
15. A method of placing a trabecular shunt for transporting aqueous humor to bypassing diseased trabecular meshwork of claim 13. wherein said existing outflow pathway is Schlemm's canal.
16. A method of placing a trabecular shunt for transporting aqueous humor to bypassing diseased trabecular meshwork of claim 14, wherein the method of heating said shape-memory Nitinol comprises delivering RF
energy from an external RF energy source through an electrical conductor to said ,stenting element and heating the stenting element to above the shape transition temperature of said shape-memory Nitinol.
energy from an external RF energy source through an electrical conductor to said ,stenting element and heating the stenting element to above the shape transition temperature of said shape-memory Nitinol.
17. A method of placing a trabecular shunt for transporting aqueous humor to bypassing diseased trabecular meshwork of claim 14, wherein the method of heating said shape-memory Nitinol comprises an external heat source adapted for heating the stenting element to above the shape transition temperature of said shape-memory Nitinol.
18. A method of delivering a trabecular shunt to bypassing diseased trabecular meshwork, the trabecular shunt comprising an inlet section and an outlet section, wherein said outlet section comprises a stenting element that is retracted during a delivery phase; the method comprising steps of:
(a) creating an opening through diseased trabecular meshwork at a size for the outlet section with a retracted scenting element to pass through;
(b) advancing the outlet section through said opening into an existing outflow pathway; and (c) expanding said retracted stenting element for stabilizing the outlet section within the existing outflow pathway.
(a) creating an opening through diseased trabecular meshwork at a size for the outlet section with a retracted scenting element to pass through;
(b) advancing the outlet section through said opening into an existing outflow pathway; and (c) expanding said retracted stenting element for stabilizing the outlet section within the existing outflow pathway.
19. A method of delivering a trabecular shunt to bypassing diseased trabecular meshwork of claim 18, wherein said stenting element is made of a shape-memory Nitinol that has a preshape and a shape transition temperature; the method of expanding said retracted stenting element comprising heating said shape-memory Nitinol to above the shape transition temperature.
20. A method of delivering a trabecular shunt to bypassing diseased trabecular meshwork of claim 19, wherein the method of heating said shape-memory Nitinol comprises an external heat source adapted for heating the stenting element to above the shape transition temperature of said shape-memory Nitinol.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US59678100A | 2000-06-19 | 2000-06-19 | |
| US09/596,781 | 2000-06-19 | ||
| PCT/US2001/018541 WO2001097727A1 (en) | 2000-06-19 | 2001-06-06 | Stented trabecular shunt and methods thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2407953A1 true CA2407953A1 (en) | 2001-12-27 |
Family
ID=24388669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002407953A Abandoned CA2407953A1 (en) | 2000-06-19 | 2001-06-06 | Stented trabecular shunt and methods thereof |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1292256A1 (en) |
| JP (1) | JP2003535646A (en) |
| AU (1) | AU2001268253A1 (en) |
| CA (1) | CA2407953A1 (en) |
| WO (1) | WO2001097727A1 (en) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8313454B2 (en) | 1997-11-20 | 2012-11-20 | Optonol Ltd. | Fluid drainage device, delivery device, and associated methods of use and manufacture |
| JP2002541975A (en) | 1999-04-26 | 2002-12-10 | ジーエムピー ヴィジョン ソルーションズ インコーポレイテッド | Trabeculotomy device and method for treatment of glaucoma |
| US6638239B1 (en) | 2000-04-14 | 2003-10-28 | Glaukos Corporation | Apparatus and method for treating glaucoma |
| US7708711B2 (en) | 2000-04-14 | 2010-05-04 | Glaukos Corporation | Ocular implant with therapeutic agents and methods thereof |
| US7867186B2 (en) | 2002-04-08 | 2011-01-11 | Glaukos Corporation | Devices and methods for treatment of ocular disorders |
| US9603741B2 (en) | 2000-05-19 | 2017-03-28 | Michael S. Berlin | Delivery system and method of use for the eye |
| US6699211B2 (en) | 2000-08-22 | 2004-03-02 | James A. Savage | Method and apparatus for treatment of glaucoma |
| US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
| AU2002258754B2 (en) | 2001-04-07 | 2006-08-17 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
| US7331984B2 (en) | 2001-08-28 | 2008-02-19 | Glaukos Corporation | Glaucoma stent for treating glaucoma and methods of use |
| US6939298B2 (en) | 2002-02-28 | 2005-09-06 | Gmp Vision Solutions, Inc | Device and method for monitoring aqueous flow within the eye |
| US7951155B2 (en) * | 2002-03-15 | 2011-05-31 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
| US20040225250A1 (en) | 2003-05-05 | 2004-11-11 | Michael Yablonski | Internal shunt and method for treating glaucoma |
| US7291125B2 (en) | 2003-11-14 | 2007-11-06 | Transcend Medical, Inc. | Ocular pressure regulation |
| CA2592459C (en) | 2004-12-16 | 2017-08-22 | Iscience Interventional Corporation | Ophthalmic implant for treatment of glaucoma |
| EP3338743A1 (en) | 2006-01-17 | 2018-06-27 | Novartis Ag | Drug delivery treatment device |
| CN101360523B (en) | 2006-01-17 | 2013-05-29 | 创森德医疗设备公司 | Glaucoma treatment device |
| US7909789B2 (en) | 2006-06-26 | 2011-03-22 | Sight Sciences, Inc. | Intraocular implants and methods and kits therefor |
| US8506515B2 (en) | 2006-11-10 | 2013-08-13 | Glaukos Corporation | Uveoscleral shunt and methods for implanting same |
| JP5328788B2 (en) | 2007-07-17 | 2013-10-30 | トランセンド・メディカル・インコーポレイテッド | Intraocular implant with hydrogel expansion capability |
| US20170360609A9 (en) | 2007-09-24 | 2017-12-21 | Ivantis, Inc. | Methods and devices for increasing aqueous humor outflow |
| US8734377B2 (en) | 2007-09-24 | 2014-05-27 | Ivantis, Inc. | Ocular implants with asymmetric flexibility |
| US20090082862A1 (en) | 2007-09-24 | 2009-03-26 | Schieber Andrew T | Ocular Implant Architectures |
| US7740604B2 (en) | 2007-09-24 | 2010-06-22 | Ivantis, Inc. | Ocular implants for placement in schlemm's canal |
| US8512404B2 (en) | 2007-11-20 | 2013-08-20 | Ivantis, Inc. | Ocular implant delivery system and method |
| US8808222B2 (en) | 2007-11-20 | 2014-08-19 | Ivantis, Inc. | Methods and apparatus for delivering ocular implants into the eye |
| US8109896B2 (en) * | 2008-02-11 | 2012-02-07 | Optonol Ltd. | Devices and methods for opening fluid passageways |
| JP2011513002A (en) | 2008-03-05 | 2011-04-28 | イバンティス インコーポレイテッド | Method and apparatus for treating glaucoma |
| ES2640867T3 (en) | 2008-06-25 | 2017-11-07 | Novartis Ag | Eye implant with ability to change shape |
| CA2972136C (en) | 2008-12-05 | 2019-08-06 | Ivantis, Inc. | Cannula for ocular implant delivery system |
| ES2920877T3 (en) | 2009-01-28 | 2022-08-11 | Alcon Inc | Ocular implant placement system |
| US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
| JP5726186B2 (en) | 2009-07-09 | 2015-05-27 | イバンティス インコーポレイテッド | Single operator device for delivering an intraocular implant |
| AU2010271218B2 (en) | 2009-07-09 | 2017-02-02 | Alcon Inc. | Ocular implants and methods for delivering ocular implants into the eye |
| CN102647960A (en) | 2009-10-23 | 2012-08-22 | 伊万提斯公司 | Ocular implant system and method |
| US8529492B2 (en) | 2009-12-23 | 2013-09-10 | Trascend Medical, Inc. | Drug delivery devices and methods |
| WO2011163505A1 (en) | 2010-06-23 | 2011-12-29 | Ivantis, Inc. | Ocular implants deployed in schlemm's canal of the eye |
| US8657776B2 (en) | 2011-06-14 | 2014-02-25 | Ivantis, Inc. | Ocular implants for delivery into the eye |
| EP2734261B1 (en) | 2011-07-18 | 2018-02-21 | Mor-Research Applications Ltd. | A device for adjusting the intraocular pressure |
| US8663150B2 (en) | 2011-12-19 | 2014-03-04 | Ivantis, Inc. | Delivering ocular implants into the eye |
| ES2961369T3 (en) | 2012-03-20 | 2024-03-11 | Sight Sciences Inc | Eye delivery systems |
| US9554940B2 (en) | 2012-03-26 | 2017-01-31 | Glaukos Corporation | System and method for delivering multiple ocular implants |
| US9358156B2 (en) | 2012-04-18 | 2016-06-07 | Invantis, Inc. | Ocular implants for delivery into an anterior chamber of the eye |
| US10085633B2 (en) | 2012-04-19 | 2018-10-02 | Novartis Ag | Direct visualization system for glaucoma treatment |
| US9241832B2 (en) | 2012-04-24 | 2016-01-26 | Transcend Medical, Inc. | Delivery system for ocular implant |
| EP3228286A1 (en) | 2012-09-17 | 2017-10-11 | Novartis AG | Expanding ocular impant devices |
| WO2014078288A1 (en) | 2012-11-14 | 2014-05-22 | Transcend Medical, Inc. | Flow promoting ocular implant |
| WO2014085450A1 (en) | 2012-11-28 | 2014-06-05 | Ivantis, Inc. | Apparatus for delivering ocular implants into an anterior chamber of the eye |
| US9592151B2 (en) | 2013-03-15 | 2017-03-14 | Glaukos Corporation | Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye |
| US10517759B2 (en) | 2013-03-15 | 2019-12-31 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
| US9987163B2 (en) | 2013-04-16 | 2018-06-05 | Novartis Ag | Device for dispensing intraocular substances |
| EP3677229A1 (en) | 2014-05-29 | 2020-07-08 | Glaukos Corporation | Implants with controlled drug delivery features |
| US10709547B2 (en) | 2014-07-14 | 2020-07-14 | Ivantis, Inc. | Ocular implant delivery system and method |
| CA2980289C (en) | 2015-03-20 | 2024-05-14 | Glaukos Corporation | Gonioscopic devices |
| US10299958B2 (en) | 2015-03-31 | 2019-05-28 | Sight Sciences, Inc. | Ocular delivery systems and methods |
| JP6837475B2 (en) | 2015-08-14 | 2021-03-03 | イバンティス インコーポレイテッド | Ocular implant and delivery system with pressure sensor |
| WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
| WO2017053885A1 (en) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
| WO2017106517A1 (en) | 2015-12-15 | 2017-06-22 | Ivantis, Inc. | Ocular implant and delivery system |
| JP7003110B2 (en) | 2016-04-20 | 2022-01-20 | ドーズ メディカル コーポレーション | Bioabsorbable eye drug delivery device |
| US10674906B2 (en) | 2017-02-24 | 2020-06-09 | Glaukos Corporation | Gonioscopes |
| US11166849B2 (en) | 2017-07-20 | 2021-11-09 | Shifamed Holdings, Llc | Adjustable flow glaucoma shunts and methods for making and using same |
| JP7191398B2 (en) | 2017-07-20 | 2022-12-19 | シファメド・ホールディングス・エルエルシー | Adjustable flow glaucoma shunt and methods of making and using same |
| US11116625B2 (en) | 2017-09-28 | 2021-09-14 | Glaukos Corporation | Apparatus and method for controlling placement of intraocular implants |
| CN110573117B (en) | 2017-10-06 | 2021-10-26 | 格劳科斯公司 | Systems and methods for delivering multiple ocular implants |
| GB201911646D0 (en) * | 2019-08-14 | 2019-09-25 | Cambridge Mechatronics Ltd | Flow control devices and methods |
| US11504270B1 (en) | 2019-09-27 | 2022-11-22 | Sight Sciences, Inc. | Ocular delivery systems and methods |
| WO2021072315A1 (en) | 2019-10-10 | 2021-04-15 | Shifamed Holdings, Llc | Adjustable flow glaucoma shunts and associated systems and methods |
| CN115379818A (en) | 2020-01-23 | 2022-11-22 | 施菲姆德控股有限责任公司 | Adjustable flow glaucoma shunt and related systems and methods |
| CN115426988A (en) | 2020-02-14 | 2022-12-02 | 施菲姆德控股有限责任公司 | Flow diversion systems having rotation-based flow control assemblies, and related systems and methods |
| US11737920B2 (en) | 2020-02-18 | 2023-08-29 | Shifamed Holdings, Llc | Adjustable flow glaucoma shunts having non-linearly arranged flow control elements, and associated systems and methods |
| WO2021188952A1 (en) | 2020-03-19 | 2021-09-23 | Shifamed Holdings, Llc | Intraocular shunts with low-profile actuation elements and associated systems and methods |
| EP4135640A4 (en) | 2020-04-16 | 2024-04-17 | Shifamed Holdings Llc | Adjustable glaucoma treatment devices and associated systems and methods |
| WO2022150684A1 (en) | 2021-01-11 | 2022-07-14 | Ivantis, Inc. | Systems and methods for viscoelastic delivery |
| EP4281144A1 (en) | 2021-01-22 | 2023-11-29 | Shifamed Holdings, LLC | Adjustable shunting systems with plate assemblies, and associated systems and methods |
| EP4176855A1 (en) * | 2021-11-09 | 2023-05-10 | Valsigna GmbH | Glaucoma implant device |
| GB202210216D0 (en) * | 2022-07-12 | 2022-08-24 | Univ Oxford Innovation Ltd | Ocular implant, kit, method of deploying |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4733665C2 (en) | 1985-11-07 | 2002-01-29 | Expandable Grafts Partnership | Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft |
| US5180362A (en) * | 1990-04-03 | 1993-01-19 | Worst J G F | Gonio seton |
| EP0898947A3 (en) * | 1997-08-15 | 1999-09-08 | GRIESHABER & CO. AG SCHAFFHAUSEN | Method and apparatus to improve the outflow of the aqueous humor of an eye |
| US6203513B1 (en) * | 1997-11-20 | 2001-03-20 | Optonol Ltd. | Flow regulating implant, method of manufacture, and delivery device |
| WO1999030641A1 (en) * | 1997-12-15 | 1999-06-24 | Prolifix Medical, Inc. | Vascular stent for reduction of restenosis |
| JP2002541975A (en) * | 1999-04-26 | 2002-12-10 | ジーエムピー ヴィジョン ソルーションズ インコーポレイテッド | Trabeculotomy device and method for treatment of glaucoma |
-
2001
- 2001-06-06 CA CA002407953A patent/CA2407953A1/en not_active Abandoned
- 2001-06-06 AU AU2001268253A patent/AU2001268253A1/en not_active Abandoned
- 2001-06-06 WO PCT/US2001/018541 patent/WO2001097727A1/en not_active Application Discontinuation
- 2001-06-06 EP EP01946172A patent/EP1292256A1/en not_active Withdrawn
- 2001-06-06 JP JP2002503205A patent/JP2003535646A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP1292256A1 (en) | 2003-03-19 |
| JP2003535646A (en) | 2003-12-02 |
| AU2001268253A1 (en) | 2002-01-02 |
| WO2001097727A1 (en) | 2001-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2407953A1 (en) | Stented trabecular shunt and methods thereof | |
| US6077298A (en) | Expandable/retractable stent and methods thereof | |
| ES2278688T3 (en) | ENDOPROTESIS COVERED OF SELF-EXPANDABLE GRAFT. | |
| RU2650203C2 (en) | Expanding ocular implant devices | |
| US6981958B1 (en) | Implant with pressure sensor for glaucoma treatment | |
| EP1137374B1 (en) | Multi-stage expandable stent-graft | |
| US6666841B2 (en) | Bifurcatable trabecular shunt for glaucoma treatment | |
| AU746903B2 (en) | Method and device to improve aqueous humor drainage in an eye | |
| US7758634B2 (en) | Bifurcated stent and delivery system | |
| US6261305B1 (en) | Endovascular prothesis with expandable leaf portion | |
| JP4850480B2 (en) | Expandable stent having a dissolvable portion | |
| US20120310137A1 (en) | Eye shunt with porous structure | |
| JPH11347133A (en) | Endoluminal supporting assembly with end cap | |
| JPH08164210A (en) | Intravascular supporting device with stent means and its manufacture | |
| WO2006036715A2 (en) | Implant and pressure sensor for glaucoma treatment | |
| JP2003518984A (en) | Manufacturing method and feeding method of artificial valve and venous artificial valve through lumen | |
| US11826089B2 (en) | Compression stent device and methods | |
| WO2024013483A1 (en) | Ocular implant, kit, method of deploying | |
| CN117379670A (en) | Ocular implant, kit for deploying an implant, and method of deploying an implant | |
| US20180070954A1 (en) | Arterial Wall Compression Stent | |
| WO1996012449A1 (en) | Connected stent apparatus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |